Polymorphism of XRCC1 Arg399Gln may predict for development of end-stage renal disease. A PCR confirmed case-control study

Abstract

ObjectivesEvaluation of the frequency of X-ray Cross Complementing group 1 (XRCC1) Arg399Gln polymorphism among patients with end-stage renal disease (ESRD) patients and to determine if a possible association was present. Subjects & methodsBlood samples were obtained from 70 ESRD patients and 30 healthy volunteers as control group for routine laboratory investigations and genomic DNA was extracted using GeneJET Whole Blood DNA Purification Kit to detect XRCC1 codon 399 genotype Arg/Gln in exon 10. BCNL digestion resulted in two fragments of 389 and 121 bp for wild-type homozygous (Arg/Arg); one fragment of 510 bp for variant homozygous (Gln/Gln); and three fragments of 510, 389 and 121 bp for variant heterozygous (Arg/Gln). ResultsCompared to control subjects, ESRD patients showed significantly higher frequency of Arg/Gln genotype, but had significantly lower frequency of Arg/Arg genotype. Moreover, patients had significantly lower frequency of Arg allele in comparison to controls (57.1% vs. 83.3%, respectively). Furthermore, the frequency of recessive models; Gln/Gln + Arg/Gln was significantly higher, while the frequency of dominant models; Arg/Arg + Arg/Gln was non-significantly lower among patients than controls. Development of ESRD was positively correlated with the presence of XRCC1 Arg/Gln genotype, while was negatively correlated with the presence of XRCC1 Arg/Arg genotype. ROC curve analysis showed that presence of XRCC1 Arg/Arg genotype is a negative sensitive predictor, while XRCC1 Arg/Gln genotype is a positive significant predictor for development of ESRD and Regression analysis defined presence of XRCC1 Arg/Arg genotype as significant negative predictor for development of ESRD. ConclusionThe results of the current study indicated an intimate relation between XRCC1 gene polymorphism and development of ESRD and the predictive value of its presence for the possibility of progression of chronic kidney disease to ESRD stage.